Revenue
2024
2025
Prelude Therapeutics Inc (PRLD)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $12.1M | $7.0M | — | — | — | — | — |
| Research & development | $94.3M | $118.0M | $103.4M | $92.9M | $86.8M | $48.2M | $24.3M |
| Operating expenses | $116.7M | $146.7M | $132.3M | $123.5M | $113.7M | $58.8M | $28.1M |
| Operating income | −$104.6M | −$139.7M | −$132.3M | −$123.5M | −$113.7M | −$58.8M | −$28.1M |
| EBITDAderived | −$102.9M | −$137.9M | −$131.1M | −$122.2M | −$112.8M | −$58.2M | −$27.7M |
| Net income | −$99.5M | −$127.2M | −$121.8M | −$115.4M | −$111.7M | −$56.9M | −$27.6M |
| Basic EPSper diluted share | -$1.29 | -$1.68 | -$2.02 | -$2.44 | -$2.43 | -$4.56 | -$16.52 |
| Diluted EPSper diluted share | -$1.29 | -$1.68 | -$2.02 | -$2.44 | -$2.43 | -$4.56 | -$16.52 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 21, 2026Form 4 | Bonita David PDirector,TenPercentOwner | BuyCommon Stock · indirect | 1.13M | $4.44 | $5.00M | 1.13M |
| Apr 21, 2026Form 4 | Bonita David PDirector,TenPercentOwner | BuyCommon Stock · indirect | 1.69M | $4.44 | $7.50M | 11.81M |
| Apr 21, 2026Form 4 | OrbiMed Genesis GP LLC +3Director,TenPercentOwner | BuyCommon Stock · indirect | 1.13M | $4.44 | $5.00M | 1.13M |
| Apr 21, 2026Form 4 | OrbiMed Genesis GP LLC +3Director,TenPercentOwner | BuyCommon Stock · indirect | 1.69M | $4.44 | $7.50M | 11.81M |
| Apr 21, 2026Form 4 | 667, L.P. +5Director,TenPercentOwner | BuyWarrants to purchase Common Stock · derivative · indirect | 2.14M | $4.44 | $9.49M | 20.11M |